Comparing Tevogen Bio (NASDAQ:TVGN) and Genfit (NASDAQ:GNFT)

Genfit (NASDAQ:GNFT) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Valuation and Earnings

This table compares Genfit and Tevogen Bio”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genfit	$76.06 million	2.52	-$31.27 million	N/A	N/A
Tevogen Bio	N/A	N/A	-$70,000.00	N/A	N/A

Tevogen Bio has lower revenue, but higher earnings than Genfit.

Profitability

This table compares Genfit and Tevogen Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genfit	N/A	N/A	N/A
Tevogen Bio	N/A	-396.07%	749.97%

Risk and Volatility

Genfit has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of -1.36, indicating that its share price is 236% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Genfit and Tevogen Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genfit	0	0	1	0	3.00
Tevogen Bio	0	0	1	0	3.00

Genfit presently has a consensus target price of $13.00, indicating a potential upside of 239.43%. Tevogen Bio has a consensus target price of $4.20, indicating a potential upside of 296.23%. Given Tevogen Bio’s higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Genfit.

Institutional & Insider Ownership

2.2% of Genfit shares are held by institutional investors. 4.2% of Genfit shares are held by insiders. Comparatively, 56.6% of Tevogen Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.